Loxo Oncology, Inc. (LOXO) CEO Joshua H. Bilenker Sells 7,500 Shares

Loxo Oncology, Inc. (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 7,500 shares of Loxo Oncology stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $86.49, for a total value of $648,675.00. Following the completion of the transaction, the chief executive officer now owns 196,207 shares of the company’s stock, valued at $16,969,943.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Loxo Oncology, Inc. (NASDAQ LOXO) opened at $81.18 on Monday. Loxo Oncology, Inc. has a 52-week low of $23.86 and a 52-week high of $95.92.

TRADEMARK VIOLATION WARNING: “Loxo Oncology, Inc. (LOXO) CEO Joshua H. Bilenker Sells 7,500 Shares” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/11/13/insider-selling-loxo-oncology-inc-loxo-ceo-sells-648675-00-in-stock.html.

A number of equities analysts have commented on LOXO shares. Morgan Stanley restated an “overweight” rating and issued a $103.00 target price (up from $95.00) on shares of Loxo Oncology in a research note on Friday, October 6th. Ifs Securities restated an “outperform” rating on shares of Loxo Oncology in a research note on Tuesday, August 8th. Citigroup Inc. restated a “buy” rating and issued a $112.00 target price (up from $86.00) on shares of Loxo Oncology in a research note on Friday, October 20th. Stifel Nicolaus restated a “buy” rating and issued a $71.00 target price on shares of Loxo Oncology in a research note on Thursday, August 3rd. Finally, BTIG Research restated a “buy” rating and issued a $102.00 target price (up from $75.00) on shares of Loxo Oncology in a research note on Friday, September 29th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Loxo Oncology has a consensus rating of “Buy” and a consensus target price of $80.02.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. boosted its position in shares of Loxo Oncology by 29.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 105,741 shares of the biopharmaceutical company’s stock worth $9,741,000 after buying an additional 24,025 shares during the period. Wells Fargo & Company MN boosted its position in shares of Loxo Oncology by 12.0% during the third quarter. Wells Fargo & Company MN now owns 18,028 shares of the biopharmaceutical company’s stock worth $1,661,000 after buying an additional 1,933 shares during the period. Amalgamated Bank acquired a new position in shares of Loxo Oncology during the third quarter worth approximately $268,000. Trexquant Investment LP acquired a new stake in Loxo Oncology in the third quarter worth approximately $367,000. Finally, Legal & General Group Plc lifted its position in Loxo Oncology by 160.1% in the third quarter. Legal & General Group Plc now owns 13,042 shares of the biopharmaceutical company’s stock worth $1,198,000 after purchasing an additional 8,028 shares during the period. Institutional investors and hedge funds own 99.31% of the company’s stock.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply